ropinirole 5mg tablets
actavis uk ltd - ropinirole hydrochloride - oral tablet - 5mg
ropinirole 5mg tablets
phoenix healthcare distribution ltd - ropinirole hydrochloride - oral tablet - 5mg
ropinirole 5mg tablets
arrow generics ltd - ropinirole hydrochloride - oral tablet - 5mg
ropinirole 5mg tablets
ranbaxy (uk) ltd - ropinirole hydrochloride - oral tablet - 5mg
ropinirole 5mg tablets
wockhardt uk ltd - ropinirole hydrochloride - oral tablet - 5mg
ropinirole 5mg tablets
waymade healthcare plc - ropinirole hydrochloride - oral tablet - 5mg
ropinirole 5mg tablets
accord-uk ltd - ropinirole hydrochloride - oral tablet - 5mg
ropinirole 5mg tablets
de pharmaceuticals - ropinirole hydrochloride - oral tablet - 5mg
ropinirole 5mg tablets
mawdsley-brooks & company ltd - ropinirole hydrochloride - oral tablet - 5mg
ropinirole tablet, film coated
unit dose services - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 1 mg - ropinirole tablets are indicated for the treatment of parkinson’s disease. ropinirole tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). ropinirole is contraindicated in patients known to have a hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or to any of the excipients. risk summary there are no adequate data on the developmental risk associated with the use of ropinirole in pregnant women. in animal studies, ropinirole had adverse effects on development when administered to pregnant rats at doses similar to (neurobehavioral impairment) or greater than (teratogenicity and embryolethality at >36 times) the maximum recommended human dose (mrhd) for parkinson’s disease. ropinirole doses associated with teratogenicity and embryolethality in pregnant rats were associated with maternal toxicity. in pregnant rabbits, ropinirole potentiated the teratogenic effects of l-dopa when these drugs were administered in combin